This new drug works by stimulating the production of antibodies in the blood. The antibodies stop nicotine from entering the brain and producing the addictive sensation craved by smokers.
The medical product has been fully effective on 50% of the 341 heavy smokers who took part in the study conducted by the Swiss pharmaceutical company Cytos Biotechnology.
Soon the world's 1.3 billion smokers might have a powerful new way to kick the habit. The vaccine approach has the potential to dramatically alter the way we will treat smoking addiction in the future.